Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers

Next Previous
Trial Profile

A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ 56914845 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 15 Jul 2013 Primary endpoint 'Left-ventricular-ejection-fraction' has been met, according to results published in Antimicrobial Agents and Chemotherapy.
  • 15 Jul 2013 Results published in Antimicrobial Agents and Chemotherapy.
  • 13 Jul 2012 Actual initiation date changed from Aug 2011 to Sept 2011 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top